Log in

Start Your Membership Now

On February 24, 2025, the U.S. Food and Drug Administration (FDA) approved Medtronic’s BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI) as a treatment to control Parkinson’s disease motor symptoms. The system self-adjusts DBS therapy to the user’s brain activity in real time, which minimizes the need for users to manually adjust the device stimulation to control motor symptom fluctuations, dyskinesias, and other side effects. The BrainSense Adaptive technology is considered a brain-computer interface (BCI).

DBS uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: